Results 41 to 50 of about 9,833 (206)
Advanced NanoBiomed Research, EarlyView.This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari +5 more
wiley +1 more source
Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats. [PDF]
PLoS ONE, 2014 BACKGROUND: Obese-insulin resistance caused by long-term high-fat diet (HFD) consumption is associated with left ventricular (LV) dysfunction and increased risk of myocardial infarction.
Nattayaporn Apaijai +4 more
doaj +1 more source
Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects [PDF]
, 2011 OBJECTIVE: Our objective was to examine the mechanisms via which exenatide attenuates postprandial hyperglycemia in type 2 diabetes mellitus (T2DM). STUDY DESIGN: Seventeen T2DM patients (44 yr; seven females, 10 males; body mass index = 33.6 kg/m(2 ...
Cersosimo, Eugenio +10 more
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.This review evaluates the available pharmacokinetic data on the plasma‐to‐breastmilk transfer of first‐ and second‐line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines.
Katherine Richardson +4 more
wiley +1 more source
JIIS: Jurnal Ilmiah Ibnu Sina, 2023 Metformin sebagai terapi Diabetes Melitus (DM) lini pertama, yang belum mampu mengontrol glukosa darah pada DM tipe 2. Salah satu golongan Dipeptidyl Peptidase IV Inhibitor (DPP4-I), yakni vildagliptin telah masuk dalam Formularium Nasional yang ...
Dwi Octamy Sari +3 more
doaj +1 more source
Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. [PDF]
, 2014 peer reviewedPatients with type 2 diabetes mellitus have an increased risk of chronic liver disease (CLD) such as non-alcoholic fatty liver disease and steatohepatitis, and about one-third of cirrhotic patients have diabetes.
Scheen, André
core +1 more source
Andrology, EarlyView.ABSTRACT Background Lichen sclerosus is a chronic, inflammatory, scarring disease of the skin that manifests mostly in the genital region. Objective We studied the histomorphological characteristics, grade, and pattern of inflammation in male pediatric patients with lichen sclerosus.
Valerie Flammang +10 more
wiley +1 more source
Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man
Frontiers in Endocrinology, 2019 Vildagliptin blocks glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) inactivation of the meal induced increases in GLP-1 and GIP so that elevated GLP-1 and GIP levels are maintained over 24 h.
James E. Foley
doaj +1 more source
Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes [PDF]
Diabetes & Metabolism Journal, 2013 BackgroundThe aims of this study are to investigate the glycemic efficacy and predictive parameters of vildagliptin therapy in Korean subjects with type 2 diabetes.MethodsIn this retrospective study, we retrieved data for subjects who were on twice-daily
Jin-Sun Chang +8 more
doaj +1 more source